High glucose and ketosis (Acetoacetate) increases, and chromium niacinate decreases, IL-6, IL-8, and MCP-1 secretion and oxidative stress in U937 monocytes

Antioxidants and Redox Signaling

Volumn 9, Issue 10, 2007, Pages 1581-1590

  Jain, Sushil K ^a   Rains, Justin L ^a   Croad, Jennifer L ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOACETIC ACID; CHROMIUM DERIVATIVE; CHROMIUM PICOLINATE; GLUCOSE; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID;

ARTICLE; CARDIOVASCULAR RISK; CELL CULTURE; CELL STRAIN U937; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; HUMAN; HUMAN CELL; INSULIN RESISTANCE; KETOACIDOSIS; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; REDUCTION; TEMPERATURE;

ANIMALS; CHROMIUM; CYTOKINES; GLUCOSE; HUMANS; KETOSIS; LIPID PEROXIDATION; OXIDATIVE STRESS; U937 CELLS;

ANIMALIA;

EID: 34648813591     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1577     Document Type: Article

References (66)

1. Abdelmegeed MA, Kim SK, Woodcraft KJ, and Novak RF. Acetoacetate activation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in primary cultured rat hepatocytes: role of oxidative stress. J Pharmacol Exp Therap 310: 728-736, 2004.
2. Abraham AS, Brooks BA, and Eylath U. Chromium and cholesterol-induced atherosclerosis in rabbits. Ann Nutr Metab 35: 203-207, 1991.
3. Ahmad SA, Gogal RM, and Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to H3-thymidine incorporation assay. J Immunol Methods 170: 211-224, 1994.
4. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, and Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46: 1786-1791, 1997.
5. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, and Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 20: 212-218, 2001.
6. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 17: 548-555, 1988.
7. Andreozzi, F, Laratta E, Cardellini M, Marini MA, Lauro R, Hribal ML, Perticone F, and Sesti G. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes 55: 2021-2024, 2006.
8. Bahijiri SM, Mira SA, Mufti AM, and Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 21: 831-837, 2000.
9. Berner TO, Murphy MM, and Slesinski R. Determining the safety of chromium tripicolinate for addition to foods as nutrient supplement. Food Chem Toxicol 42: 1029-1042, 2004.
10. Brownlee M. The pathogenesis of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005.
11. Bruun JM, Helge JW, Richelsen B, and Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol 290: E961-967, 2006.
12. Castelnau PA, Garrett RS, Palinski W, Witztum JL, Campbell IL, and Powell HC. Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol 57: 268-282, 1998.
13. Candiloros H, Muller S, Zeghari N, Donner M, Drouin P, and Ziegler O. Decreased erythrocyte membrane fluidity in poorly controlled IDDM. Influence of ketone bodies. Diabetes Care 18: 549-551, 1995.
14. Cefalu WT and Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 27: 2741-2751, 2004.
15. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, and Russell JC. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 132: 1107-1114, 2002.
16. Cheng HH, Lai MH, Hou WC, and Huang CL. Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic subjects. J Agric Food Chem 52: 1385-1389, 2004.
17. Chromium and Diabetes Workshop. Published by the Office of Dietary Supplements, National Institutes of Health, Bethesda, MD ( 1999). (http://ods.nih.gov/news/conferences/chromium_diabetes.html, accessed November 2006).
18. Cuzzocrea S, De Sarro G, Costantino G, Ciliberto G, Mazzon E, De Sarro A, and Caputi AP. IL-6 knockout mice exhibit resistance to splanchnic artery occlusion shock. J Leukoc Biol 66: 471-480, 1999.
19. Debasis B, Stohs SJ, Downs BW, Bagchi M, and Preuss HG. Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology 180:5-22, 2002.
20. Esterbauer H, Lang J, Zadravec S, and Slater T. Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol 105: 319-328, 1984.
21. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, and Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398: 718-723, 1999.
22. Guallar EJF, van't Veer P, Bode P, Riemersma R, Gomez-Aracena J, Kark J, Arab L, Kok F, and Martin-Moreno JM. Toenail chromium and risk of myocardial infarction. Am J Epidemiol 162:157-164, 2005.
23. Guha M, Bai W, Nadler JL, and Natarajan R. Molecular mechanisms of tumor necrosis factor a gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 275: 17728-17739, 2000.
24. Hepburn DDD, Xiao J, Bindom S, Vincent JB, and O'Donnell J. Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster. Proc Natl Acad Sci 100: 3766-3771, 2003.
25. Hoffman WH, Cheng C, Passmore GG, Carroll JE, and Hess D. Acetoacetate increases expression of intracellular adhesion molecule-1 (ICAM-1) in human brain microvascular endothelial cells. Neurosci Lett 334: 71-74, 2002.
26. Huber SA, Sakkinen P, Conze D, Hardin N, and Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364-2367, 1999.
27. Jain SK, Kannan K, Lim G, Matthew-Greer J, McVie R, and Bocchini JA. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 26: 2139-2143, 2003.
28. Jain SK, Kannan K, and Lim G. Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells. Free Rad Biol Med 25: 1083-1088, 1998.
29. Jain SK and Kannan K. Chromium chloride inhibits oxidative stress and TNF-á secretion caused by exposure to high glucose in cultured monocytes. Biochem Biophys Res Commun 289: 687-691, 2001.
30. Jain SK, Kannan K, Lim G, McVie R, Bocchini JA. Hyperketonemia increases TNF-a secretion in cultured U937 monocytes and type-1 diabetic patients and is mediated by oxidative stress and cAMP-deficiency. Diabetes 51: 2287-2293, 2002.
31. Jain SK, Patel P, Rogier K, and Jain SK. Trivalent chromium inhibits protein glycation and lipid peroxidation in high glucose treated erythrocytes. Antioxid Redox Signal 8: 238-241, 2006.
32. Jain SK. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem 264: 21340-21345, 1989.
33. Kado, S, Nagase, T., Nagata, N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 36: 67-72, 1999.
34. Kamei N, Tobe K, Szuki R, Ohsugi M, Watanabe R, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, and Kadowaki T . Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-26614, 2006.
35. Lefavi RG, Wison GD, Keith RE, Anderson RA, Blessing DL, Hames CG, et al. Lipid lowering effect of dietary chromium (III)-nicotinic acid complex in male atheletes. Nutr Res 13: 239-249, 1993.
36. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 15: 412-426, 1999.
37. Lamson DM and Plaza SM. The safety and efficacy of high-dose chromium. Alt Med Rev 7: 218-235, 2002.
38. Lee NA and Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 17: 1449-1452, 1994.
39. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, and Cefalu WT. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29: 1826-1832, 2006.
40. McDonnell CM, Pedreira CC, Vadamalayan B, Cameron FJ, and Werther GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high carbohydrate drinks wosening initial presentation. Ped Diabetes 6: 90-94, 2005.
41. Morris BW, MacNeil S, Hardisty CA, Heller S, Burgin C, and Gray TA. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 13: 57-61, 1999.
42. Mossop RT. Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. Cent Afr J Med 29: 80-82, 1983.
43. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani, G, Illig T, Thorand B, and Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45: 805-812, 2002.
44. Murthy K, Harrington JT, and Siegel RD. Profound hypokalemia in diabetic ketoacidosis: A therapeutic challenge. Endocrine Practice 5: 331-334, 2005.
45. Natarajan R, Lanting L, Gonzales N, and Nadler J. Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 271: 159-165, 1996.
46. Newton CA and Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. Arch Intern Med 164: 1925-1931, 2004.
47. Noh H, Ha H, Yu MR, Kim YO, Kim JH, and Lee HB. Angiotension II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Pent Dial Int 25: 38-47, 2005.
48. Pineau A, Guillard O, and Risse JF. A study of chromium in human cataractous lenses and whole blood of diabetics, senile, and normal population. Biol Trace Elem Res 32: 133-138, 1992.
49. Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willett WC, and Hu FB. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 27: 2211-2116, 2004.
50. Rink C, Roy S, Khanna S, Rink T, Bagchi D, and Sen CK. Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Lepr obese diabetic mice with niacin-bound chromium. Physiol Genom 27: 370-379, 2007.
51. Rotter V, Nagaev I, and Smith U. Interleukin-6 induces insulin resistance in 3T3-L1 adipocytes and is like IL-8 and tumor necrosis factor-a overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 46: 45777-45784, 2003.
52. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, and Nathan DM. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111: 2446-2453, 2005.
53. Siesinski RS, Clarke JJ, San RH, and Gudi R. Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells. Mutation Res 585: 86-95, 2005.
54. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, and Coulhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the UK. Diabetes Care 29: 798-804, 2006.
55. Speetjens JK, Collins RA, Vincent JB, and Woski SA. The nutritional supplement chromium (III) tris(picolinate) cleaves DNA. Chem Res Toxicol 12: 483-487, 1999.
56. Stearns DM, Wise JP Sr. Patierno SR, and Wetterhahn KE. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 9: 1643-1649, 1995.
57. Stenz FB, Umpierrez GE, Cuervo R, and Kitabachi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53: 2079-2086, 2004.
58. Terkeltaub R, Boisvert WA, and Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 9: 397-405, 1998.
59. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329: 977-986, 1993.
60. Umpierrez GE and Kitabchi AE. Diabetic ketoacidosis: risk factors and management. Treat Endocrinol 3: 95-108, 2003.
61. Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 63: 41-47, 2004.
62. Vinson JA, Mandarano MA, Shuta DL, Bagchi M, and Bagchi D. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model. Mol Cell Biochem 240: 99-103, 2002.
63. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, and Ferrante AW Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124, 2006.
64. Yang X, Palanichamy K, Ontko AC, Rao MNA, Fang CX, Ren J, and Sreejayan N. A newly synthetic chromium complex-chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucoe tolerance. FEBS Lett 579: 1458-1464, 2005.
65. Yared Z and Chiasson JI. Ketoacidosis and hyperosmolar hyperglycemic state in adult diabetic patients. Minerva Med 94: 909-913, 2003.
66. Yerneni KK, Bai W, Khan BV, Medford RM, and Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48: 855-864, 1999.